| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4256461 | Transplantation Proceedings | 2014 | 4 Pages |
Abstract
BackgroundNew-onset diabetes after transplantation is associated with an increase in risk of graft failure, cardiovascular disease, and mortality. Therefore, it compromises the overall beneficial outcome of organ transplantation.Case ReportA patient with new-onset diabetes after renal transplantation showed glucose and lipid metabolism improvements after switching immunosuppressant from everolimus to cyclosporin A. A subcutaneous adipose tissue biopsy displayed changes in gene and protein expression that could contribute to the clinical improvement of hyperglycemia and dyslipidemia.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
M.J. Pereira, J.W. Eriksson, M.K. Svensson,